无排斥反应时供者特异性抗体并非移植物失败的危险因素
该研究纳入2013至2016年间在威斯康星大学接受肾移植活检且无急性排斥或显著急性病理特征的患者587例,按活检时DSA状态分为DSA阳性组192例和阴性组395例。中位随访33.1个月,多因素分析显示后续排斥或DSA(包括移植前、新生、持续、I/II类、MFI总和或最大值)与移植物失败均无关联。结论提示在活检无排斥和急性炎症时,HLA DSA与移植物失败风险增加无关。
要点
- 无活检证实的排斥和急性炎症时,DSA阳性不增加移植物失败风险。
- DSA阴性组死亡删失移植物失败发生率更高,但后续排斥无差异。
- 移植至活检间隔、新生DSA和较年轻年龄与后续排斥独立相关。
核心结论
- 在活检无排斥反应且无急性炎症的情况下,HLA供者特异性抗体与移植物失败风险增加无关。
研究设计与样本
- 回顾性队列研究,纳入威斯康星大学2013年1月1日至2016年12月31日期间接受肾移植活检且无急性排斥或显著急性病理特征的患者587例(DSA阳性192例,DSA阴性395例)。
主要发现
- 活检时两组急性Banff评分均为0,慢性Banff评分分别为2.4±2.2和2.7±2.4,cg评分分别为0.12±0.48和0.13±0.48,无差异。
- 平均随访33.1±16.8个月,Kaplan-Meier分析显示DSA阴性组死亡删失移植物失败发生率更高(n=83),但后续排斥发生率无差异(n=76)。
- 多因素Cox回归分析中,移植至活检间隔、新生DSA和较年轻年龄与后续排斥风险增加独立相关。
- 后续排斥或DSA(移植前、新生、持续、I/II类、MFI总和或最大值)与移植物失败均无关联。
临床怎么用
- 对于活检无排斥且无急性炎症的肾移植受者,DSA阳性本身不应被视为移植物失败的危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Donor-specific antibodies (DSAs) are considered an important risk factor for graft injury and failure. However, there is limited information on long-term outcomes for kidney transplant recipients with positive DSAs in the absence of rejection on biopsy. METHODS: We evaluated all patients at the University of Wisconsin who underwent a kidney allograft biopsy between January 1, 2013, and December 31, 2016. All patients with clinical indication or protocol biopsies that were negative for acute rejection and lacked significant acute pathological features were included in the study and divided into 2 groups based on DSAs at the time of biopsy. There were a total of 1102 kidney biopsies during the study period of which 587 fulfilled our selection criteria (DSA+, n = 192, and DSA-, n = 395). The incidence of subsequent rejection and death-censored graft failure (DCGF) were outcomes of interest. RESULTS: There was no difference in acute (i + t + v + c4d + ptc + g = 0 in both groups) or chronic (ci + ct + cv + cg = 2.4 ± 2.2 vs. 2.7 ± 2.4; cg = 0.12 ± 0.48 vs. 0.13 ± 0.48) Banff scores in the index biopsy. Patients were followed for a mean of 33.1 ± 16.8 months. Kaplan-Meier analyses demonstrated a higher incidence of DCGF in DSA- group (n = 83) but this was not observed for subsequent rejection (n = 76). In multivariate Cox regression analyses, the interval from transplant to biopsy, de novo DSA, and younger age remained independently associated with increased risk of subsequent rejection. Notably, there was no association between subsequent rejection or DSA (pretransplant, de novo, persistant, Class I/II, MFIsum, or MFImax) and graft failure. CONCLUSION: This study suggests that in the absence of biopsy-proven rejection and acute inflammation, human leukocyte antigen (HLA) DSAs are not associated with increased risk of graft failure.
引用
- Parajuli S, Joachim E, Alagusundaramoorthy S, et al. Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure. Kidney Int Rep. 2019. PMID: 31440696. doi:10.1016/j.ekir.2019.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。